QED Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- QED Therapeutics's estimated annual revenue is currently $5.7M per year.
- QED Therapeutics received $65.0M in venture funding in January 2018.
- QED Therapeutics's estimated revenue per employee is $77,500
- QED Therapeutics's total funding is $65M.
- QED Therapeutics has 74 Employees.
- QED Therapeutics grew their employee count by -11% last year.
QED Therapeutics Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is QED Therapeutics?
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.keywords:N/A
Number of Employees
Employee Growth %
QED Therapeutics News
... HER2 negative Breast Cancer treatment therapies, as per DelveInsight ... QED Therapeutics, Inc., Tyme, Inc., PIQUR Therapeutics, Pfizer,...
Sarepta Therapeutics is also focused on the disease. ... comes about a year after BridgeBio launched QED Therapeutics to develop infigratinib, ...
SAN FRANCISCO, June 3, 2019 /PRNewswire/ -- QED Therapeutics announced today the presentation of data demonstrating the clinical ...
SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- QED Therapeutics announced today the presentation of preclinical data demonstrating the ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
QED Therapeutics Funding